Table 1.
Bortezomib-based induction therapy: summary of results of phase 3 randomized trials
B indicates bortezomib; T, thalidomide; D, dexamethasone; V, vincristine; A, Adriamycin; and P, prednisone.
Bortezomib-based induction therapy: summary of results of phase 3 randomized trials
B indicates bortezomib; T, thalidomide; D, dexamethasone; V, vincristine; A, Adriamycin; and P, prednisone.
